A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Academic Curriculum Components Bookmark and Share

Academic Curriculum Components

Clinical Cancer Genetics Course
All trainees in City of Hope’s Cancer Genetics Career Development Program (CGCDP) are required to complete this 16-week course. This course provides a comprehensive knowledge base in cancer genetics, including the following:
 
  • Carcinogenesis: cellular, molecular, genetic and environmental etiology
  • Clinical features, pathology, epidemiology and treatment of cancer
  • Hereditary cancer syndromes
  • Cancer risk assessment
  • Cancer genetic counseling skills development
  • Genetic testing: legal, ethical and insurance issues related to genetic testing
  • Role of cancer registries and clinical research trials
 
Curriculum materials are developed as a ten-day, 60-hour CME-accredited intensive course, which is also open to cancer risk counselors in underserved communities.

The course curriculum is updated periodically under the direction of the Advisory Committee to accommodate the rapid developments in cancer genetics knowledge. Faculty and trainees have the opportunity to deliver selected lectures and update course content.
 
Cancer Genetics Working Group
The CME-accredited Clinical Cancer Genetics Working Group is comprised of experts from various disciplines who discuss cases and the best care for each patient. The Working Group convenes weekly to:

Review all Cancer Screening & Prevention Program Network (CSPPN) patient and family case histories Discuss cancer risk assessment, genetic test results interpretation and management strategies Discuss case-related interpersonal and familial psychosocial issues, and candidacy for chemopreventive, epidemiological and behavioral research protocolsThe rich clinical experience, coupled with multidisciplinary case discussion, form the cornerstone of the program's experiential training.
 
Topics in Clinical Cancer Genetics
A weekly lecture series focuses on issues in clinical cancer genetics and cancer genetics research, alternating between didactic lectures and “journal club.” Participants comment on and interpret primary research reports on key topics in molecular cancer genetics, risk assessment, epidemiological and behavioral research, and clinical cancer prevention. They learn how to present findings in summary form and incorporate important research findings into clinical practice and research projects. This lecture series is a primary forum for updates. A list of these topics and attachments to the related articles are also posted on our WebBoard, “The Genetics Link.”

The Genetics Link is City of Hope’s Clinical Cancer Genetics web forum. To expand their practical knowledge in the field of clinical cancer genetics, members of this discussion group exchange ideas and receive valuable feedback from experts and from one another. Membership in The Genetics Link is open by invitation only and to those who have been part of the Clinical Cancer Genetics Technology Transfer Research (CCGTTR) courses and outreach activities.
 
In collaboration with Dr. Stanley Azen, Director of the USC Graduate Programs in Biometry and Epidemiology, a dual-track customized curriculum in cancer epidemiology was initiated with University of Southern California (USC). The curriculum consists of two modules, in which trainees enroll concurrently.
 
All trainees are required to participate in selected topics.

 

 

Academic Curriculum Components

Academic Curriculum Components

Clinical Cancer Genetics Course
All trainees in City of Hope’s Cancer Genetics Career Development Program (CGCDP) are required to complete this 16-week course. This course provides a comprehensive knowledge base in cancer genetics, including the following:
 
  • Carcinogenesis: cellular, molecular, genetic and environmental etiology
  • Clinical features, pathology, epidemiology and treatment of cancer
  • Hereditary cancer syndromes
  • Cancer risk assessment
  • Cancer genetic counseling skills development
  • Genetic testing: legal, ethical and insurance issues related to genetic testing
  • Role of cancer registries and clinical research trials
 
Curriculum materials are developed as a ten-day, 60-hour CME-accredited intensive course, which is also open to cancer risk counselors in underserved communities.

The course curriculum is updated periodically under the direction of the Advisory Committee to accommodate the rapid developments in cancer genetics knowledge. Faculty and trainees have the opportunity to deliver selected lectures and update course content.
 
Cancer Genetics Working Group
The CME-accredited Clinical Cancer Genetics Working Group is comprised of experts from various disciplines who discuss cases and the best care for each patient. The Working Group convenes weekly to:

Review all Cancer Screening & Prevention Program Network (CSPPN) patient and family case histories Discuss cancer risk assessment, genetic test results interpretation and management strategies Discuss case-related interpersonal and familial psychosocial issues, and candidacy for chemopreventive, epidemiological and behavioral research protocolsThe rich clinical experience, coupled with multidisciplinary case discussion, form the cornerstone of the program's experiential training.
 
Topics in Clinical Cancer Genetics
A weekly lecture series focuses on issues in clinical cancer genetics and cancer genetics research, alternating between didactic lectures and “journal club.” Participants comment on and interpret primary research reports on key topics in molecular cancer genetics, risk assessment, epidemiological and behavioral research, and clinical cancer prevention. They learn how to present findings in summary form and incorporate important research findings into clinical practice and research projects. This lecture series is a primary forum for updates. A list of these topics and attachments to the related articles are also posted on our WebBoard, “The Genetics Link.”

The Genetics Link is City of Hope’s Clinical Cancer Genetics web forum. To expand their practical knowledge in the field of clinical cancer genetics, members of this discussion group exchange ideas and receive valuable feedback from experts and from one another. Membership in The Genetics Link is open by invitation only and to those who have been part of the Clinical Cancer Genetics Technology Transfer Research (CCGTTR) courses and outreach activities.
 
In collaboration with Dr. Stanley Azen, Director of the USC Graduate Programs in Biometry and Epidemiology, a dual-track customized curriculum in cancer epidemiology was initiated with University of Southern California (USC). The curriculum consists of two modules, in which trainees enroll concurrently.
 
All trainees are required to participate in selected topics.

 

 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 


NEWS & UPDATES
  • Every summer, hospitals nationwide experience a shortage of blood donations. This summer is no exception. Nearly 1.7 million new cancer cases are expected to be diagnosed in the U.S. this year,  and many of those patients will need blood transfusions during their treatment. Patients at City of Hope alone rely o...
  • Non-Hodgkin lymphoma facts: Non-Hodgkin lymphoma is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Lymphocytes are in the lymph nodes and other lymphoid tissues (such as the spleen and bone marrow). Non-Hodgkin lymphoma is one of the most common cancers in the U.S....
  • Few clinical cancer trials include older adults – and yet, more than 60 percent of cancer cases in the United States occur in people age 65 and older. The result is a dearth of knowledge on how to treat the very population most likely to be diagnosed with cancer. Now, the American Society of Clinical […]
  • Scientists at City of Hope and UCLA have become the first to inhibit the expression of a protein, called TWIST that promotes tumor invasion and metastasis when activated by cancer cells. As such, they’ve taken the first step in developing a potential new therapy for some of the deadliest cancers, including ovar...
  • Upon completing her final round of chemotherapy for ovarian cancer earlier this month, Maria Velazquez-McIntyre, a 51-year-old Antelope Valley resident, celebrated the milestone by giving other patients a symbol of hope – a Survivor Bell. The bell may look ordinary, but for cancer patients undergoing chemothera...
  • Many Americans understand that obesity is tied to heart disease and diabetes but, according to a new survey, too few – only 7 percent – know that obesity increases the risk of cancer. Specific biological characteristics can increase cancer risk in obese people, and multiple studies have shown correlations betwe...
  • As breast cancer survivors know, the disease’s impact lingers in ways both big and small long after treatment has ended. A new study suggests that weight gain – and a possible corresponding increase in heart disease and diabetes risk – may be part of that impact. In the first study to evaluate weight chan...
  • Becoming what’s known as an independent scientific researcher is no small task, especially when working to translate research into meaningful health outcomes. Yet that independent status is vital, enabling researchers to lead studies and avenues of inquiry that they believe to be promising. Clinicians, especial...
  • 720 days. That’s how long Alex Tung, 38, had to give up surfing after being diagnosed with acute myeloid leukemia. For most people, even some surfers, such a hiatus wouldn’t be a big deal, but for Tung, surfing has been everything. The Southern California resident began surfing when he was in elemen...
  • There are few among us who have not experienced loss of a friend or loved one, often without warning, or like those of us who care for people with cancer, after a lingering illness. It is a time when emotions run high and deep, and as time passes from the moment of loss, we often […]
  • For the past four years, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., has been studying how breast cancer cells spread, or metastasize, to the brain, where they become life-threatening tumors. Known as secondary brain tumors, these cancers have become increasingly common as treatment advances have ena...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. A primary symptom is a rash that arises initially in areas of the skin that are not normally exposed to sunlight....
  • There’s science camp, and then there’s “mystery” science camp. City of Hope’s new science camp for middle school students is of the especially engaging latter variety. From Monday, July 13, to Friday, July 17, rising middle-school students from across the San Gabriel Valley were presented with a “patient” with ...
  • Women diagnosed with breast cancer quickly learn their tumor’s type, meaning the characteristics that fuel its growth. That label guides the treatment of their disease, as well as their prognosis when it comes to treatment effectiveness. Sometimes, however, doctors can’t accurately predict treatment effectivene...
  • In years past, Bladder Cancer Awareness Month has been a sobering reminder of a disease with few treatment options. For patients with metastatic disease (disease that has spread from the bladder to distant organs), average survival is typically just over one year. Fortunately, things are changing. Academic inst...